According to The British Society for Rheumatology guidelines, 5.6% of outpatients with rheumatoid arthritis (RA) in the West Midlands, UK, are eligible for anti-tumour necrosis factor (TNF) monoclonal antibody therapy

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 422, 2003-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

The Future Role of Anti-Tumour Necrosis Factor (TNF) Products in the Treatment of Rheumatoid Arthritis

By Camussi G.   Lupia E.  

Drugs, Vol. 55, Iss. 5, 1998-05 ,pp. : 613-620

Adis International

Access to resources Recommend Favorite

Anti-Tumour Necrosis Factor-α Therapy for Rheumatoid and Other Inflammatory Arthropathies: Update on Safety in Older Patients

By Ornetti Paul   Chevillotte Hélène   Zerrak Amal   Jean Francis Maillefert  

Drugs & Aging, Vol. 23, Iss. 11, 2006-01 ,pp. : 855-860

Adis International

Access to resources Recommend Favorite

Local versus Systemic Anti-Tumour Necrosis Factor-α Effects of Adalimumab in Rheumatoid Arthritis: Pharmacokinetic Modelling Analysis of Interaction between a Soluble Target and a Drug

By Stepensky David  

Clinical Pharmacokinetics, Vol. 51, Iss. 7, 2012-07 ,pp. : 443-455

Adis International

Access to resources Recommend Favorite

Tumour necrosis factor blockade in rheumatoid arthritis

By Breedveld Ferdinand C  

Clinical Medicine, Vol. 1, Iss. 2, 2001-03 ,pp. : 107-109

Royal College Of Physicians

Access to resources Recommend Favorite